(KVUE) Kenvue - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US49177J1025
KVUE: Health, Beauty, Care, Medicine, Skin, Hair
Kenvue Inc. (NYSE:KVUE) is a global consumer health powerhouse, spun out from Johnson & Johnson in 2022. The company operates through three distinct segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care division is a market leader in over-the-counter (OTC) medications, offering trusted brands like Tylenol, Motrin, and Zyrtec, which dominate the cough, cold, allergy, and pain relief categories. This segment also includes nicotine cessation products under Nicorette and digestive health solutions like Imodium, catering to everyday health needs.
The Skin Health and Beauty segment boasts a robust portfolio of personal care brands, including Neutrogena, Aveeno, and Dr. Ci:Labo. These brands are recognized for their dermatologically tested products, ranging from face and body care to sun and hair products. This division capitalizes on the growing demand for science-backed, premium skincare and beauty products, positioning Kenvue as a key player in the $500 billion global beauty and personal care market.
The Essential Health segment focuses on daily wellness and hygiene products, featuring iconic brands like Listerine, Johnsons, and Band-Aid. This division also includes baby care, womens health, and wound care products, such as Johnsons baby lotions and ointments, as well as feminine hygiene products under Stayfree and Carefree. These offerings are staples in millions of households, providing steady cash flows and brand loyalty.
From a financial perspective, Kenvue trades on the NYSE under the ticker KVUE, with a market capitalization of ~$38 billion. The stock currently carries a trailing P/E of 36.67 and a forward P/E of 16.37, reflecting expectations of future earnings growth. Its price-to-book ratio of 3.57 and price-to-sales ratio of 2.46 indicate a premium valuation, consistent with its strong brand portfolio and market position. Headquartered in Skillman, New Jersey, Kenvue is well-positioned to leverage its heritage as a J&J spin-off, combining a legacy of innovation with the agility of a standalone company. For more information, visit their website at https://www.kenvue.com.
Additional Sources for KVUE Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
KVUE Stock Overview
Market Cap in USD | 44,761m |
Sector | Consumer Defensive |
Industry | Household & Personal Products |
GiC Sub-Industry | Personal Care Products |
IPO / Inception | 2023-05-04 |
KVUE Stock Ratings
Growth 5y | 2.53% |
Fundamental | 13.0% |
Dividend | 62.9% |
Rel. Strength Industry | 9.2 |
Analysts | 3.53/5 |
Fair Price Momentum | 22.39 USD |
Fair Price DCF | 16.14 USD |
KVUE Dividends
Dividend Yield 12m | 3.72% |
Yield on Cost 5y | 3.24% |
Annual Growth 5y | 42.30% |
Payout Consistency | 100.0% |
KVUE Growth Ratios
Growth Correlation 3m | 44.8% |
Growth Correlation 12m | 68.3% |
Growth Correlation 5y | -0.9% |
CAGR 5y | -5.08% |
CAGR/Max DD 5y | -0.15 |
Sharpe Ratio 12m | -0.55 |
Alpha | 12.79 |
Beta | 0.18 |
Volatility | 27.45% |
Current Volume | 15798.9k |
Average Volume 20d | 16116.4k |
As of March 15, 2025, the stock is trading at USD 22.81 with a total of 15,798,911 shares traded.
Over the past week, the price has changed by -2.60%, over one month by +4.01%, over three months by +4.38% and over the past year by +18.14%.
Neither. Based on ValueRay Fundamental Analyses, Kenvue is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 13.04 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KVUE as of March 2025 is 22.39. This means that KVUE is currently overvalued and has a potential downside of -1.84%.
Kenvue has received a consensus analysts rating of 3.53. Therefor, it is recommend to hold KVUE.
- Strong Buy: 3
- Buy: 3
- Hold: 11
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, KVUE Kenvue will be worth about 24.2 in March 2026. The stock is currently trading at 22.81. This means that the stock has a potential upside of +6.01%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 23.8 | 4.3% |
Analysts Target Price | 25 | 9.5% |
ValueRay Target Price | 24.2 | 6% |